“Decreased percent change in renal pelvis diameter on diuretic functional magnetic resonance urography following administration of furosemide may help characterize unilateral uretero-pelvic junction obstruction”
We read the article by Janssen et  al. entitled “Decreased percent change in renal pelvis diameter on diuretic functional magnetic resonance urography following administration of furosemide may help characterize unilateral uretero-pelvic junction obstruction” with great interest [1]. Janssen et al. indicated that a relatively smaller change in anterior-posterior renal pelvic diameter (APRPD) on functional magnetic resonance urography (fMRU) following administration of furosemide in ureteropelvic junction obstruction may be predictive for obstructed kidneys [1]. (Source: Journal of Pediatric Urology)
Source: Journal of Pediatric Urology - March 14, 2024 Category: Urology & Nephrology Authors: Oktay Ulusoy, Mustafa Olguner Tags: Letter to the Editor Source Type: research

Predicting Stone-free Status based on Quadruple-D and Triple-D Scores after Extracorporeal Shock-Wave Lithotripsy and Comparing With Broad-Spectrum Population
CONCLUSIONS: The Quadruple-D score is at least as successful as the Triple-D score in predicting SWL success.PMID:38479426 | DOI:10.1055/a-2266-3564 (Source: Aktuelle Urologie)
Source: Aktuelle Urologie - March 13, 2024 Category: Urology & Nephrology Authors: Alper Co şkun Utku Can Source Type: research

Fluorofenidone attenuates renal fibrosis by inhibiting lysosomal cathepsin ‑mediated NLRP3 inflammasome activation
Exp Ther Med. 2024 Feb 15;27(4):142. doi: 10.3892/etm.2024.12430. eCollection 2024 Apr.ABSTRACTCurrently, no antifibrotic drug in clinical use can effectively treat renal fibrosis. Fluorofenidone (AKFPD), a novel pyridone agent, significantly reduces renal fibrosis by inhibiting the activation of the NOD-like receptor thermal protein domain associated protein 3 (NLRP3) inflammasome; however, the underlying mechanism of this inhibition is not fully understood. The present study aimed to reveal the molecular mechanism underlying the suppression of NLRP3 inflammasome activation by AKFPD. It investigated the effect of AKFPD on...
Source: Experimental and Therapeutic Medicine - March 13, 2024 Category: General Medicine Authors: Linfeng Zheng Wenjuan Mei Jing Zhou Xin Wei Zhijuan Huang Xiaozhen Lin Li Zhang Wei Liu Qian Wu Jinhong Li Yan Yan Source Type: research

Predicting Stone-free Status based on Quadruple-D and Triple-D Scores after Extracorporeal Shock-Wave Lithotripsy and Comparing With Broad-Spectrum Population
CONCLUSIONS: The Quadruple-D score is at least as successful as the Triple-D score in predicting SWL success.PMID:38479426 | DOI:10.1055/a-2266-3564 (Source: Aktuelle Urologie)
Source: Aktuelle Urologie - March 13, 2024 Category: Urology & Nephrology Authors: Alper Co şkun Utku Can Source Type: research

Fluorofenidone attenuates renal fibrosis by inhibiting lysosomal cathepsin ‑mediated NLRP3 inflammasome activation
Exp Ther Med. 2024 Feb 15;27(4):142. doi: 10.3892/etm.2024.12430. eCollection 2024 Apr.ABSTRACTCurrently, no antifibrotic drug in clinical use can effectively treat renal fibrosis. Fluorofenidone (AKFPD), a novel pyridone agent, significantly reduces renal fibrosis by inhibiting the activation of the NOD-like receptor thermal protein domain associated protein 3 (NLRP3) inflammasome; however, the underlying mechanism of this inhibition is not fully understood. The present study aimed to reveal the molecular mechanism underlying the suppression of NLRP3 inflammasome activation by AKFPD. It investigated the effect of AKFPD on...
Source: Experimental and Therapeutic Medicine - March 13, 2024 Category: General Medicine Authors: Linfeng Zheng Wenjuan Mei Jing Zhou Xin Wei Zhijuan Huang Xiaozhen Lin Li Zhang Wei Liu Qian Wu Jinhong Li Yan Yan Source Type: research

Predicting Stone-free Status based on Quadruple-D and Triple-D Scores after Extracorporeal Shock-Wave Lithotripsy and Comparing With Broad-Spectrum Population
CONCLUSIONS: The Quadruple-D score is at least as successful as the Triple-D score in predicting SWL success.PMID:38479426 | DOI:10.1055/a-2266-3564 (Source: Aktuelle Urologie)
Source: Aktuelle Urologie - March 13, 2024 Category: Urology & Nephrology Authors: Alper Co şkun Utku Can Source Type: research

Fluorofenidone attenuates renal fibrosis by inhibiting lysosomal cathepsin ‑mediated NLRP3 inflammasome activation
Exp Ther Med. 2024 Feb 15;27(4):142. doi: 10.3892/etm.2024.12430. eCollection 2024 Apr.ABSTRACTCurrently, no antifibrotic drug in clinical use can effectively treat renal fibrosis. Fluorofenidone (AKFPD), a novel pyridone agent, significantly reduces renal fibrosis by inhibiting the activation of the NOD-like receptor thermal protein domain associated protein 3 (NLRP3) inflammasome; however, the underlying mechanism of this inhibition is not fully understood. The present study aimed to reveal the molecular mechanism underlying the suppression of NLRP3 inflammasome activation by AKFPD. It investigated the effect of AKFPD on...
Source: Experimental and Therapeutic Medicine - March 13, 2024 Category: General Medicine Authors: Linfeng Zheng Wenjuan Mei Jing Zhou Xin Wei Zhijuan Huang Xiaozhen Lin Li Zhang Wei Liu Qian Wu Jinhong Li Yan Yan Source Type: research

Predicting Stone-free Status based on Quadruple-D and Triple-D Scores after Extracorporeal Shock-Wave Lithotripsy and Comparing With Broad-Spectrum Population
CONCLUSIONS: The Quadruple-D score is at least as successful as the Triple-D score in predicting SWL success.PMID:38479426 | DOI:10.1055/a-2266-3564 (Source: Aktuelle Urologie)
Source: Aktuelle Urologie - March 13, 2024 Category: Urology & Nephrology Authors: Alper Co şkun Utku Can Source Type: research

Fluorofenidone attenuates renal fibrosis by inhibiting lysosomal cathepsin ‑mediated NLRP3 inflammasome activation
Exp Ther Med. 2024 Feb 15;27(4):142. doi: 10.3892/etm.2024.12430. eCollection 2024 Apr.ABSTRACTCurrently, no antifibrotic drug in clinical use can effectively treat renal fibrosis. Fluorofenidone (AKFPD), a novel pyridone agent, significantly reduces renal fibrosis by inhibiting the activation of the NOD-like receptor thermal protein domain associated protein 3 (NLRP3) inflammasome; however, the underlying mechanism of this inhibition is not fully understood. The present study aimed to reveal the molecular mechanism underlying the suppression of NLRP3 inflammasome activation by AKFPD. It investigated the effect of AKFPD on...
Source: Experimental and Therapeutic Medicine - March 13, 2024 Category: General Medicine Authors: Linfeng Zheng Wenjuan Mei Jing Zhou Xin Wei Zhijuan Huang Xiaozhen Lin Li Zhang Wei Liu Qian Wu Jinhong Li Yan Yan Source Type: research

Predicting Stone-free Status based on Quadruple-D and Triple-D Scores after Extracorporeal Shock-Wave Lithotripsy and Comparing With Broad-Spectrum Population
CONCLUSIONS: The Quadruple-D score is at least as successful as the Triple-D score in predicting SWL success.PMID:38479426 | DOI:10.1055/a-2266-3564 (Source: Aktuelle Urologie)
Source: Aktuelle Urologie - March 13, 2024 Category: Urology & Nephrology Authors: Alper Co şkun Utku Can Source Type: research

Fluorofenidone attenuates renal fibrosis by inhibiting lysosomal cathepsin ‑mediated NLRP3 inflammasome activation
Exp Ther Med. 2024 Feb 15;27(4):142. doi: 10.3892/etm.2024.12430. eCollection 2024 Apr.ABSTRACTCurrently, no antifibrotic drug in clinical use can effectively treat renal fibrosis. Fluorofenidone (AKFPD), a novel pyridone agent, significantly reduces renal fibrosis by inhibiting the activation of the NOD-like receptor thermal protein domain associated protein 3 (NLRP3) inflammasome; however, the underlying mechanism of this inhibition is not fully understood. The present study aimed to reveal the molecular mechanism underlying the suppression of NLRP3 inflammasome activation by AKFPD. It investigated the effect of AKFPD on...
Source: Experimental and Therapeutic Medicine - March 13, 2024 Category: General Medicine Authors: Linfeng Zheng Wenjuan Mei Jing Zhou Xin Wei Zhijuan Huang Xiaozhen Lin Li Zhang Wei Liu Qian Wu Jinhong Li Yan Yan Source Type: research

Predicting Stone-free Status based on Quadruple-D and Triple-D Scores after Extracorporeal Shock-Wave Lithotripsy and Comparing With Broad-Spectrum Population
CONCLUSIONS: The Quadruple-D score is at least as successful as the Triple-D score in predicting SWL success.PMID:38479426 | DOI:10.1055/a-2266-3564 (Source: Aktuelle Urologie)
Source: Aktuelle Urologie - March 13, 2024 Category: Urology & Nephrology Authors: Alper Co şkun Utku Can Source Type: research

Fluorofenidone attenuates renal fibrosis by inhibiting lysosomal cathepsin ‑mediated NLRP3 inflammasome activation
Exp Ther Med. 2024 Feb 15;27(4):142. doi: 10.3892/etm.2024.12430. eCollection 2024 Apr.ABSTRACTCurrently, no antifibrotic drug in clinical use can effectively treat renal fibrosis. Fluorofenidone (AKFPD), a novel pyridone agent, significantly reduces renal fibrosis by inhibiting the activation of the NOD-like receptor thermal protein domain associated protein 3 (NLRP3) inflammasome; however, the underlying mechanism of this inhibition is not fully understood. The present study aimed to reveal the molecular mechanism underlying the suppression of NLRP3 inflammasome activation by AKFPD. It investigated the effect of AKFPD on...
Source: Experimental and Therapeutic Medicine - March 13, 2024 Category: General Medicine Authors: Linfeng Zheng Wenjuan Mei Jing Zhou Xin Wei Zhijuan Huang Xiaozhen Lin Li Zhang Wei Liu Qian Wu Jinhong Li Yan Yan Source Type: research

Predicting Stone-free Status based on Quadruple-D and Triple-D Scores after Extracorporeal Shock-Wave Lithotripsy and Comparing With Broad-Spectrum Population
CONCLUSIONS: The Quadruple-D score is at least as successful as the Triple-D score in predicting SWL success.PMID:38479426 | DOI:10.1055/a-2266-3564 (Source: Aktuelle Urologie)
Source: Aktuelle Urologie - March 13, 2024 Category: Urology & Nephrology Authors: Alper Co şkun Utku Can Source Type: research

Fluorofenidone attenuates renal fibrosis by inhibiting lysosomal cathepsin ‑mediated NLRP3 inflammasome activation
Exp Ther Med. 2024 Feb 15;27(4):142. doi: 10.3892/etm.2024.12430. eCollection 2024 Apr.ABSTRACTCurrently, no antifibrotic drug in clinical use can effectively treat renal fibrosis. Fluorofenidone (AKFPD), a novel pyridone agent, significantly reduces renal fibrosis by inhibiting the activation of the NOD-like receptor thermal protein domain associated protein 3 (NLRP3) inflammasome; however, the underlying mechanism of this inhibition is not fully understood. The present study aimed to reveal the molecular mechanism underlying the suppression of NLRP3 inflammasome activation by AKFPD. It investigated the effect of AKFPD on...
Source: Experimental and Therapeutic Medicine - March 13, 2024 Category: General Medicine Authors: Linfeng Zheng Wenjuan Mei Jing Zhou Xin Wei Zhijuan Huang Xiaozhen Lin Li Zhang Wei Liu Qian Wu Jinhong Li Yan Yan Source Type: research